Comparative bioavailability of a cisapride suppository and tablet formulation in healthy volunteers

Eur J Clin Pharmacol. 1990;38(6):629-31. doi: 10.1007/BF00278595.


The comparative bioavailability of cisapride as a 30 mg suppository and three 5 mg oral tablets was investigated in 12 non-smoking, healthy male volunteers. The two formulations were administered on two separate occasions following an overnight fast, according to a randomized cross-over design. The plasma concentration of cisapride was measured over 48 h after drug administration. The 30 mg suppository exhibited a mean time to the peak plasma concentration of 3.8 h, while the tablets showed a significantly earlier peak time of 1.5 h. The maximum plasma concentration of cisapride after the 30 mg suppository (50.3 was significantly lower than after the tablets (74.3 The AUCs following the two treatments did not differ significantly from each other. The comparative bioavailability of the 30 mg cisapride suppository in relation to the three 5 mg oral tablets was 85%, with a 95%-confidence interval of 67% to 102% (not adjusted for dose). Normalizing the mean AUC by dose, the relative bioavailability of the suppository was 43% of that of the tablet. The elimination half-life of cisapride was not significantly different following the administration of the two formulations (9.3 h for the suppository and 9.8 h for the tablet).

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Biological Availability
  • Cisapride
  • Half-Life
  • Humans
  • Male
  • Piperidines / administration & dosage
  • Piperidines / pharmacokinetics*
  • Random Allocation
  • Suppositories
  • Tablets


  • Piperidines
  • Suppositories
  • Tablets
  • Cisapride